Recently, second-generation antipsychotics (SGAs), olanzapine plus fluoxetine, quetiapine extended release and aripiprazole have clearly demonstrated efficacy in the treatment of MDD patients ...

There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). Methods This open-label, pilot study was designed to investigate the efficacy ...

Treatment-resistant depression (TRD) occurs when major depressive disorder (MDD) treatment does not work. There is no official definition or set criteria for TRD, but the measure often used is an ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

With so many options available, it’s important to consult your doctor to understand how each treatment works and to determine the best options to treat your condition. Topical treatments are ...

For acute major depression, this form of therapy typically takes place once a week and lasts ... Talk to your healthcare provider about the best depression treatment approach for you, including the ...

agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder ...

In a post-hoc analysis, the company found statistically significant improvement versus placebo consistent across both investigator and patient measures of MDD in female subjects, which was ...

SP-624 is also currently being studied in a large Phase 2b study in patients diagnosed with MDD, with efficacy in ... over placebo during a 4-week treatment period. In a post-hoc analysis, the ...